Dedicated to ending the HIV epidemic — dr. moupali das, MD, MPH, executive director, HIV clinical research, gilead sciences.
Dr. Moupali Das, MD, MPH, is Executive Director, HIV Clinical Research, in the Virology Therapeutic Area, at Gilead Sciences (https://www.gilead.com/), where she leads the pre-exposure prophylaxis (PrEP) clinical drug development program, including evaluating the safety and efficacy of a long-acting, twice yearly, subcutaneous injection being studied for HIV prevention. Her responsibilities also include expanding the populations who may benefit from PrEP.
Dr. Das has led high-performing teams in academic medicine, public health, implementation science, and cross-functionally in drug development. She has successfully helped develop, implement, and evaluate how to better test, link to care, increase virologic suppression, and improve quality of life for people with HIV, and to prevent HIV in those who may benefit from PrEP.